Resource data sheet
DNA Bank Top
Please review the QC test results indicated by check icon below as well as clone information before placing your order.

pENTER-EGFR L858R (#RDB15493)

Gateway(R) entry vector of human epidermal growth factor receptor (EGFR), EGFR-activating mutation.

Clone info. Gateway(R) entry vector of human epidermal growth factor receptor (EGFR) mutant, L858R in exon 21, EGFR-activating mutation.
Comment cDNA was obtained from A549 cells. Expression was confirmed by the depositor with western blotting after cloned into pLenti6.3 vector (by LR clonase II reaction). This clone contains a cDNA fragment corresponding to the 258nt to 3890nt of NM_005228.4. Known differences (at least) : G to A substitution at 2618nt (Q, synonym) ; T to G substitution at 2830nt (L858R).
Vector backbone pENTR (plasmid)
Size of vector backbone 2.6 kb
Selectable markers Kan^r
Gene/insert name human EGFR cDNA
Depositor|Developer Katayama, Ryohei |
 

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
Please visit Information of Request for Distribution.[link] 
Terms and conditions for distribution In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature designated by the DEPOSITOR is requested. (Uchibori, K et al. Nat. Commun. 8: 14768, 2017)
Remarks
Gateway® Entry clone. Please refer Life Technologies Corporation signs license agreement with RIKEN BRC.
提供案内 (日本国内) [open/close]

必要書類
提供依頼書  [依頼書の記入例 ]
提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ]
手続きの概要は、「提供申込みについて[link]」をご覧ください。
MTAに書く使用条件 利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する(Uchibori, K et al. Nat. Commun. 8: 14768, 2017)。
備考
Gateway®テクノロジーを用いたエントリークローンです。「Gateway®テクノロジーを用いたクローンの提供と寄託のご案内」をご覧ください。

Catalog # Resource name Shipping form Fee (non-profit org.)
RDB15493 pENTER-EGFR L858R DNA solution

Please review the QC test results indicated by check icon below as well as clone information before placing your order.

How to cite this biological resource

Materials & Methods section:

The pENTER-EGFR L858R was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB15493).

Reference section:

Uchibori, K., Inase, N., Araki, M., Kamada, M., Sato, S., Okuno, Y., Fujita, N., Katayama, R., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. [link to RRC of NBRP]

Further references such as user reports and related articles (go to bottom)

QC test results

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check icon as well as clone information before placing your order.

Test sheet RDB15493_A7K8p1-2.pdf check

Nucleotide sequence of a portion of this resource (if available).

Primer: rrnBT1ter_F2 (Pr0531)
Region: rrnB T1 ter,attL1,insert 5'
Sequence file: RDB15493_A7K8d.seq check
>D04925A6_A7K8_2_rrnBT1ter_F2_F04_16_ABI24.ab1
    1 NNNNNNNNNN NNNNNNNNNN NCCTTTCGTT TTNTTTGATG CCTGGCAGTT CCCTACTCTC
   61 GCGTTAACGC TAGCATGGAT GTTTTCCCAG TCACGACGTT GTAAAACGAC GGCCAGTCTT
  121 AAGCTCGGGC CCCAAATAAT GATTTTATTT TGACTGATAG TGACCTGTTC GTTGCAACAA
  181 ATTGATGAGC AATGCTTTTT TATAATGCCA ACTTTGTACA AAAAAGCAGG CTCCGCGGCC
  241 GCCCCCTTCA CCATGCGACC CTCCGGGACG GCCGGGGCAG CGCTCCTGGC GCTGCTGGCT
  301 GCGCTCTGCC CGGCGAGTCG GGCTCTGGAG GAAAAGAAAG TTTGCCAAGG CACGAGTAAC
  361 AAGCTCACGC AGTTGGGCAC TTTTGAAGAT CATTTTCTCA GCCTCCAGAG GATGTTCAAT
  421 AACTGTGAGG TGGTCCTTGG GAATTTGGAA ATTANNNATG TGCAGAGGAA TTATGATCTT
  481 TCCTTCTTAA AGACCATCCA GGAGGTGGCT GGTTATGTCC TCATTGCCCT CAACACAGTG
  541 GAGCGAATTC CTTTGGAAAA CCTGCAGATC ATCAGAGGAA ATATGTACTA CGAAAATTCC
  601 TATGCCTTAG CAGTCTTATC TAACTATGAT GCAAATAAAA CCGGACTGAA GGAGCTGCCC
  661 ATGAGAAATT TACAGGAAAT CCTGCATGGC GCCGTGCGGT TCAGCAACAA CCCTGCCCTG
  721 TGCAATGTGG AGAGCATCCA GTGGCGGGAC ATAGTCAGCA GTGACTTTCT CAGCAACATG
  781 TCGATGGACT TCCAGAACCA CCTGGGCAGC TGCCAAAAGT GTGATCCAAG CTGTCNNAAN
  841 GNNANCTGCT GGGGTGCANG NNANGANAAN TGCCAGAAAC TGANCAAANT CATCTGTGCC
  901 CAGCAGTGNN NCNGGNGCTG CCNNNGNAAN NNCCCCCANN NNNNGCNNNC NCAACCANNN
961 NNNTNNNNNN NNNN
//
Primer: pDONR_R (Pr0071)
Region: attL2,insert 3'
Sequence file: RDB15493_A7K8e.seq check
>D04925A6_A7K8_2_pDONR_R_H05_23_ABI24.ab1
    1 NNNNNNNNNN NNNNNNCNNT GNNNNTGTNA TACGACTCNC TATAGGGGAN ATCAGCTGGA
   61 TGGCAAATAA TGATTTTATT TTGACTGATA GTGACCTGTT CGTTGCAACA AATTGATAAG
  121 CAATGCTTTC TTATAATGCC AACTTTGTAC AAGAAAGCTG GGTCGGCGCG CCCACCCTTT
  181 CATGCTCCAA TAAATTCACT GCTTTGTGGC GCGACCCTTA GGTATTCTGC ATTTTCAGCT
  241 GTGGAGCCCT TAAAGATGCC ATTTGGCTTG GCTTCCTTGG GAAAGAAGTC CTGCTGGTAG
  301 TCAGGGTTGT CCAGGCTAAT TTGGTGGCTG CCTTTCTGGG CCCAGTGGGC AGGGCTGTCG
  361 AATGTGCTGT TGACACAGGT GGGCTGGACA GTGTTGAGAT ACTCGGGGTT GCCCACTGCA
  421 GTGCTGTGGG GGTCCTGGTA GTGTGGGTCT CTGCTGGGCG CGGGGTTCAG AGGCTGATTG
  481 TGATAGACAG GATTCTGCAC AGAGCCAGCG GGCCTTTTGG GAACGGACTG GTTTATGTAT
  541 TCAGGCACTG GGAGGAAGGT GTCGTCTATG CTGTCCTCAG TCAAGGCGCC TGTGGGGTCT
  601 GAGCTGTATC GCTGCAAGAA GCTGTCTTCC TTGATGGGAC AGCTTTGCAG CCCATTTCTA
  661 TCAATGCAAG CCACGGTGGA ATTGTTGCTG GTTGCACTCA GAGAGCTCAN GANGGGAGTC
  721 CGTGACGTGG ANGGGCTGCT GAANAAGCCC TGCTGTGGGA NGANGTACTC GTCGGCATCC
  781 ACCACGTCGT CCATGTCTTC TTCATCCNTC NNGNCACGGT ANAAGTTGGA NTCTGTANGA
  841 NTTNNCAAAT GCATTCTTTC NTCCCCCCNG ANTGANAAGG NANCGCTNGG GGGTCNCGGG
  901 CCNNTTTNGG ANNANNTCNA TGANCNNNTC NNNGNANNNT TNGGNNNANN ATCTGCNNCT
961 ATNNNNNNNN NN
//
Primer: EGFR-F5 (Pr0313)
Region: insert mid (L858R)
Sequence file: RDB15493_A7K8f.seq check
>D04925A6_A7K8_2_EGFR-F5_F09_18_ABI24.ab1
    1 NNNNNNNNNN NNNNNNNNNN NNNGGNNGGT GGGGGCCCTC CTCTTGCTGC TGGTGGTGGC
   61 CCTGGGGNNC GGCCTCTTCA TGCGAAGGCG CCACATCGTT CGGAAGCGCA CGCTGCGGAG
  121 GCTGCTGCAG GAGAGGGAGC TTGTGGAGCC TCTTACACCC AGTGGAGAAG CTCCCAACCA
  181 AGCTCTCTTG AGGATCTTGA AGGAAACTGA ATTCAAAAAG ATCAAAGTGC TGGGCTCCGG
  241 TGCGTTCGGC ACGGTGTATA AGGGACTCTG GATCCCAGAA GGTGAGAAAG TTAAAATTCC
  301 CGTCGCTATC AAGGAATTAA GAGAAGCAAC ATCTCCGAAA GCCAACAAGG AAATCCTCGA
  361 TGAAGCCTAC GTGATGGCCA GCGTGGACAA CCCCCACGTG TGCCGCCTGC TGGGCATCTG
  421 CCTCACCTCC ACCGTGCAAC TCATCACGCA GCTCATGCCC TTCGGCTGCC TCCTGGACTA
  481 TGTCCGGGAA CACAAAGACA ATATTGGCTC CCAGTACCTG CTCAACTGGT GTGTGCAGAT
  541 CGCAAAGGGC ATGAACTACT TGGAGGACCG TCGCTTGGTG CACCGCGACC TGGCAGCCAG
  601 GAACGTACTG GTGAAAACAC CGCAGCATGT CAAGATCACA GATTTTGGGC GGGCCAAACT
  661 GCTGGGTGCG GAAGAGAAAG AATACCATGC AGAAGGAGGC AAAGTGCCTA TCAAGTGGAT
  721 GGCATTGGAA TCAATTTTAC ACAGAATCTA TACCCACCAG AGTGATGTCT GGAGCTACNG
  781 GGTGACCGTT TGNGAGTTGA TGANCTTTGG ATCCNAGCCA TATGACGGAA TCCCTGCCAG
  841 CGNNNTCTCC TCCATCCTGG ANAAAGGANA ANGCCTCCCT CANNCNCCCA TATNNACCAT
  901 CNNTGTCTAC NTNNNCNTGG NCAANNNNTN NNNGNNANNC GNNNNNANTC NCCNNANNNT
961 NNNNNNNNNN
//

Please visit Sequencing and PCR primers for primer information.

References

Original, user report and related articles

original Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. [link to RRC of NBRP]